Login to Your Account

Financings Roundup

Aegerion Seeks $47.3M After FDA Accepts Lomitapide NDA

By Marie Powers
Staff Writer

Friday, June 15, 2012
A month after the FDA accepted its new drug application (NDA) for lead compound lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in patients with homozygous familial hypercholesteremia (HoFH) and familial chylomicronemia (FC), Aegerion Pharmaceuticals Inc. priced an underwritten public offering of 3.4 million shares of common stock at $14.75 each, seeking to raise approximately $47.3 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription